Review of icatibant use in the Winnipeg Regional Health Authority

Table 4 Final clinical outcome (FCO) and times to onset of symptom relief (OSR) and achievement of FCO

Category	n	Stratification	Hours (95% CI)	Reference value	p-value (*< 0.05)
FCO available	21	Any outcome	NA	NA	NA
	18	Fully resolved
	3	Discharged without complete resolution
Median time to OSR	21	All	1.34 (1.00–5.63)	0.8^b	0.04*
	10	HAE vs natural history	1.13 (0.75–NE)	0.8^b 3.5^b	0.34 0.10
	9^a	ACEI-induced (n = 9) vs. natural history	4.86 (2.17–NE)	0.8^b 1.6^c	0.01* 0.29
	14	Face/oropharolarynx symptoms present	2.17 (0.83–NE)	0.7^b	0.09
	7	Face/oropharolarynx symptoms not present	1.00 (0.75–NE)	0.8^b	0.45
Median time to FCO	21	All groups	7.75 (2.5–43.41)	8.0^b	1.00
	10	HAE vs natural history	3.50 (1.83–NE)	8.0^b 36.0^b	0.11 0.02*
	9^a	ACEI-induced vs. natural history	19.53 (8.13–NE)	4.5^b 4.0^c	0.18 0.18
	14	Face/oropharolarynx symptoms present	8.93 (4.67–73.28)	6.0^b	0.42
	7	Face/oropharolarynx symptoms not present	2.18 (1.83–NE)	8.0^b	0.45
Median time from attack onset to icatibant dose	10	HAE	9.58 (8.20–NE)	Pairwise	0.80
Median time from attack onset to icatibant dose	9	ACEI-induced	16.53 (4.25–NE)	Pairwise	0.80

FCO Final clinical outcome, OSR onset of symptom relief, NE not estimable, NA not applicable
^aTwo presentations were for neither HAE or ACEIIAE
^bFrom Lumry et al. [5]
^cFrom Sinert et al. [4]

ISSN: 1710-1492